HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Charo, J. Articles by Kiessling, R. Search for Related Content PubMed PubMed Citation Articles by Charo, J. Articles by Kiessling, R.

A Long-Term Memory Obtained by Genetic Immunization Results in Full Protection from a Mammary Adenocarcinoma Expressing an EBV Gene¹

Jehad Charo^2,*,, Anne-Marie T. Ciupitu^*,, Alain Le Chevalier de Préville^*, Pankaj Trivedi^3,, George Klein, Jorma Hinkula and Rolf Kiessling^*,

^* Cancer Center Karolinska (CCK), Karolinsk Hospital, Stockholm, Sweden; Microbiolgy and Tumorbiology Center (MTC), Karolinska Institute, Stockholm, Sweden; and Swedish Institute for Infectious Disease Control, Stockholm, Sweden

We have tested the capability of a plasmid DNA (pDNA) expressing the EBV nuclear Ag-4 (EBNA-4) to evoke a T cell response-associated protective immune response against a tumor expressing this gene. We have found that ACA mice immunized with EBNA-4-expressing plasmid were partially protected against syngeneic mammary carcinoma line (S6C) expressing EBNA-4 (S6C-E4). This protection was enhanced by coimmunizing mice with EBNA-4- and GM-CSF-expressing plasmids, and a full protection was achieved by coimmunizing mice with EBNA-4- and IFN--expressing plasmids. Furthermore, mice that have rejected the EBNA-4-positive tumor were also resistant against a subsequent challenge with the original nontransfected tumor line. We then checked for the ability of pDNA immunization to provide a protective long-term memory response. We indeed found that even after 3 mo from the last immunization, full protection was obtained by this method, as compared with full tumor outgrowth in the control-immunized group. These findings support the concept that a nonviral, pDNA-based vaccination strategy is useful to fully protect from the outgrowth of tumors expressing this EBV gene.

This article has been cited by other articles:

				J. Charo, J. A. Lindencrona, L.-M. Carlson, J. Hinkula, and R. Kiessling Protective Efficacy of a DNA Influenza Virus Vaccine Is Markedly Increased by the Coadministration of a Schiff Base-Forming Drug J. Virol., October 15, 2004; 78(20): 11321 - 11326. [Abstract] [Full Text] [PDF]

				J. Charo, M. Sundback, K. Wasserman, A.-M. T. Ciupitu, B. Mirzai, R. van der Zee, and R. Kiessling Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug Infect. Immun., December 1, 2002; 70(12): 6652 - 6657. [Abstract] [Full Text] [PDF]

				K. Haupt, M. Roggendorf, and K. Mann The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237. [Abstract] [Full Text] [PDF]

				M. P. Piechocki, S. A. Pilon, and W.-Z. Wei Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2 J. Immunol., September 15, 2001; 167(6): 3367 - 3374. [Abstract] [Full Text] [PDF]